Authors: Jouffroy R, Jost D, Prunet B PMID: 32513249 PMCID: PMC7278215 doi: 10.1186/s13054-020-03036-9 Abstract The COVID-19 pandemic, which has been expanding since the first cases in Asia in late 2019, may result in acute respiratory failure (ARF) with severe hypoxemia [1–3]. In prehospital settings, the paucity of clinical respiratory signs has made assessing the severity [...]

Authors: Janowitz T, Baglenz E, Pattinson D, Wang TC, Conigliaro J PMID: 32499303 PMCID: PMC7299656 DOI: 10.1136/gutjnl-2020-321852 Abstract Objective: Treatment options for non-hospitalised patients with coronavirus disease 2019 (COVID-19) to reduce morbidity, mortality and spread of the disease are an urgent global need. The over-the-counter histamine-2 receptor antagonist famotidine is a putative therapy for COVID-19. [...]

Authors: Chowdhury AT, Shahbaz M, Karim MR, Islam J, Dan G DOI: 10.14744/ejmo.2021.16263 Abstract Objectives: We investigated the outcomes of Ivermectin-Doxycycline vs. Hydroxychloroquine-Azithromycin combination therapy in mild to moderate COVID19 patients. Methods: Patients were divided randomly into two groups: Ivermectin 200µgm/kg single dose + Doxycycline 100mg BID for ten days in group A, and Hydroxychloroquine [...]

Authors: Henriquez MS, de Tejada Romero MJ PMID: 32486496 PMCID: PMC7352679 doi: 10.3390/nu12061617 Abstract Vitamin D deficiency is a global health problem due to its high prevalence and its negative consequences on musculoskeletal and extra-skeletal health. In our comparative review of the two exogenous vitamin D supplementation options most used in our care setting, we [...]

Authors: Merchant HA DOI: 10.14293/S2199-1006.1.SOR-.PPURWMT.v1 Abstract While we wait for a confirmed drug or a vaccine for CoViD-19, it may be possible to intervene early to prevent the virus causing a severe disease to offer an alternative therapeutic strategy to control the pandemic. The global burden of CoViD-19 on healthcare system can be significantly reduced [...]

Authors: Freedberg DE, Conigliaro J, Sobieszczyk ME, Markowitz DD PMID: 32446698 PMCID: PMC7242191 doi: 10.1053/j.gastro.2020.05.053 Abstract Coronavirus Disease 2019 (COVID-19) caused 2 million cases and more than 150,000 deaths worldwide as of mid-April 2020.1 Clinical trials are under way to assess the efficacy of a variety of antiviral drugs; however, many of these drugs have [...]

Authors: Dayer MR doi: 10.20944/preprints202005.0020.v1 Abstract The disease of COVID-19 comprises the most serious against human health worldwide with a high rate of virulence and mortality. The disease is caused by the 2019-nCoV virus from the beta coronavirus family. The virus makes use of its surface glycoprotein named S protein or spike to enter the [...]

Authors: Padmanabhan S, Padmanabhan K DOI:10.13140/RG.2.2.22854.83527 Abstract COVID-19 has tested the limits of our healthcare system with very few clear therapeutic options proven to date. Previous studies of SARS and MERS and now SARS-CoV-2 have clearly shown the significance of interferon response in altering disease severity/outcome. The broad anti-viral activity of Nitazoxanide stems from its [...]

Nair MP, Kandaswami C, Mahajan S, Chadha KC, Chawda R, Nair H. PMID: 12431781 DOI: 10.1016/s0167-4889(02)00328-2 Abstract Flavonoids are plant metabolites that are dietary antioxidants and exert significant anti-tumor, anti-allergic, anti-inflammatory and anti-viral effects. It is generally accepted that Th-1 derived cytokines such as IL-2, IFNgamma and IL-12 promote cellular immunity while Th-2 derived [...]

Authors: Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. PMID: 32251768 PMCID: PMC7129059 DOI: 10.1016/j.antiviral.2020.104787 Abstract Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum [...]